Wednesday - November 18, 2026
FDA Center for Drug Evaluation & Research Issues Warning Letter to Shenzhen Benliju Biotech
November 18, 2026
WASHINGTON, Nov. 18 (TNSdock) -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Shenzhen Benliju Biotech Co., Ltd. from its Center for Drug Evaluation and Research:

* * *

Recipient: Mr. Xiaojun Xu, General Manager, Shenzhen Benliju Biotech Co., Ltd., Factory Building 303, Qihong Pinshun Industrial Park, 105 Pinshun Road, Guixiang Community, Guanlan Street, Shenzhen Shi Guangdong Sheng, 518000, China

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products